13F Holdings
中文EN

MPLT MapLight Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1770069 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-145.1%
TTM EPS YoY162.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-293.7%
ROA-68.6%
ROIC (approx.)-812.4%
Asset turnover—

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio9.53x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-20.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$138.35M$68.52M
SG&A expense$30.73M$14.42M
Operating income-$169.08M-$82.95M
Net income-$161.15M-$77.58M
EBITDA-$168.50M-$82.25M
EPS (basic)-18.56-105.38
EPS (diluted)-18.56-105.38
Weighted avg. shares (diluted)8.68M736,178
Balance sheet
Cash & equivalents$46.73M$38.25M
Short-term investments$258.37M$70.54M
Current assets$324.67M$114.60M
PP&E, net$1.09M$1.21M
Total assets$479.51M$136.92M
Current liabilities$16.23M$15.92M
Total liabilities$21.14M$21.72M
Shareholders' equity$458.37M-$193.63M
Shares outstanding44.02M761,276
Cash flow statement
Operating cash flow-$138.14M-$78.81M
Capital expenditure$473,000$770,000
Free cash flow-$138.61M-$79.58M
Investing cash flow-$323.21M-$80.79M
Financing cash flow$469.82M$118.06M
Depreciation & amortization$578,000$701,000
Stock-based compensation$36.01M$1.08M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.